Galera Therapeutics

Galera Therapeutics, Inc. specializes in developing therapies for breast cancer treatment.00 mn.Galera Therapeutics, Inc. specializes in developing innovative therapies specifically targeting breast cancer treatment. The company's core product offerings revolve around proprietary technologies designed to enhance the anti-cancer efficacy of existing therapies, ultimately aiming to provide improved treatment outcomes for patients. These novel therapies focus on addressing significant unmet medical needs in the breast cancer patient population and enhancing the quality of life.Galera Therapeutics generates revenue through partnerships and collaborations within the healthcare sector, primarily focusing on pharmaceutical companies and clinical research organizations. The firm’s revenue model capitalizes on the successful development and commercialization of its flagship therapeutics, which are positioned to impact breast cancer treatment paradigms.00 mn in a private placement to support the completion of its Phase 3 clinical trial. The company aims to launch new therapies designed to further enhance treatment options for breast cancer patients. Additionally, Galera is looking to expand its market presence into select international regions, with specific strategies being developed for these efforts.

1. Series C

   Aug 30, 2018

   Amount

   $70M

   Investors

   Locked

2. Series B

   Nov 28, 2016

   Amount

   $15M

   Investors

   Locked

3. Series B

   Feb 3, 2016

   Amount

   $5M

   Investors

   Locked

4. Series B

   Oct 14, 2015

   Amount

   $37M

   Investors

   Locked

5. Series A

   Mar 19, 2015

   Amount

   $4.7M

   Investors

   Locked

6. Series A

   Aug 6, 2014

   Amount

   $4.7M

   Investors

   Locked

7. Series A

   Dec 10, 2012

   Amount

   $11M

   Investors

   Locked

8. Seed

   Jun 15, 2010

   Amount

   Undisclosed

   Investors

   Locked